New hope for rare disease: drug may slash steroid dependence
NCT ID NCT05030155
First seen Nov 20, 2025 · Last updated Jun 09, 2026 · Updated 24 times
Summary
This study tests if a drug called mepolizumab can help people with a rare disease called EGPA (which causes inflammation in blood vessels, asthma, and sinus problems) use less steroids while keeping the disease under control. About 100 adults with active EGPA will receive either mepolizumab or standard treatment. The main goal is to see if more people on mepolizumab can lower their daily steroid dose to 4 mg or less without having a relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques "Hôpital Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.